Bioceltix S.A. (WSE:BCX)

Poland flag Poland · Delayed Price · Currency is PLN
104.00
+3.20 (3.17%)
Aug 13, 2025, 4:44 PM CET
3.17%
Market Cap517.07M
Revenue (ttm)n/a
Net Income (ttm)-14.49M
Shares Out4.92M
EPS (ttm)-3.06
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,134
Average Volume3,832
Open105.00
Previous Close100.80
Day's Range103.00 - 107.40
52-Week Range66.00 - 129.00
Beta1.37
RSI51.41
Earnings DateSep 18, 2025

About Paramount Global

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 36
Stock Exchange Warsaw Stock Exchange
Ticker Symbol BCX
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.